• Overview
  • Eligibility
  • More info
  • Locations

Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (NCT03029858)

The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor (EGFR)T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.
  • Other: No interventions will be taken in this Observational study
    TAGRISSO(osimertinib/AZD9291)
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    Inclusion Criteria:
    • The patient enrolled in ASTRIS or patient who are eligible for the ASTRIS study.
    • The patient is willing to provide informed consent form to provide specimen before osimertinib treatment and at the time of PD.
    • Patients must be able to undergo a fresh tumor biopsy during screening or to provide an available tumor sample taken <2 months prior to screening.
    • Fine needle aspirate specimens are not acceptable.
    • Specimens from metastatic bone lesions are typically unacceptable unless there is confirmed soft tissue component.
    • The tumor specimen submitted to establish eligibility should be of sufficient quantity to allow for PD-L1 IHC and other biomarker analyses (if applicable) and is preferred in formalin-fixed paraffin embedded blocks.
    Exclusion Criteria:
    • The patient does not have sufficient tumor tissue specimen available for detection.
    • The Patient who is unwilling to use the existing data from medical practice for scientific research.
    • The patient who received immunotherapy therapy before.
    Investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced EGFR T790M positive advanced NSCLC patients.

    explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.

    12 locations

    China (12)
    • Fujian Medical University Union Hospital
      Not specified
      Fuzhou, Fujian, China
    • Fujian Principal Cancer Hospital
      Not specified
      Fuzhou, Fujian, China
    • The first Affiliated Hospital of Nanchang University
      Not specified
      Nanchang, Jiangxi, China
    • The second affiliated hospital of Nanchang University
      Not specified
      Nanchang, Jiangxi, China
    • Fudan University Shanghai Cancer Center
      not yet recruiting
      Shanghai, Shanghai, China
    • Shanghai Chest Hospital Oncology dept.
      not yet recruiting
      Shanghai, Shanghai, China
    • Shanghai Chest Hospital Respiratory dept.
      not yet recruiting
      Shanghai, Shanghai, China
    • The first Affiliated hospital of Zhejiang University, Thoracic Oncology Dept.
      Not specified
      Hangzhou, Zhejiang, China
    • The first Affiliated hospital of Zhejiang University,Respiratory dept.
      Not specified
      Hangzhou, Zhejiang, China
    • The second Affiliated hospital of Zhejiang University of Medicine
      Not specified
      Hangzhou, Zhejiang, China
    • Zhejiang Cancer Hospital
      Not specified
      Hangzhou, Zhejiang, China
    • Zhejiang Taizhou Hospital
      Not specified
      Taizhou, Zhejiang, China
    Status:
    not yet recruiting
    Type:
    Observational
    Phase:
    -
    Start:
    31 December, 2016
    Updated:
    19 January, 2017
    Participants:
    155
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!